Research Progress on Oral Nano-formulation to Deliver Astaxanthin

ZHONG Chen; LIU Mei; GAO Yan; XU Kefeng; WANG Ying

doi:10.13386/j.issn1002-0306.2023070028

Volume 45 Issue 10

May 2024

Turn off MathJax

Article Contents

Abstract

References

Supplements

Science and Technology of Food Industry > 2024 > 45(10): 395-400. > DOI: 10.13386/j.issn1002-0306.2023070028

ZHONG Chen, LIU Mei, GAO Yan, et al. Research Progress on Oral Nano-formulation to Deliver Astaxanthin[J]. Science and Technology of Food Industry, 2024, 45(10): 395−400. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2023070028.

Citation:

PDF (1154 KB)

Research Progress on Oral Nano-formulation to Deliver Astaxanthin

ZHONG Chen^1,,
LIU Mei¹,
GAO Yan¹,
XU Kefeng¹,
WANG Ying^{1, 2, ,}

1.
Marine Science Research Institute of Shandong Province, Qingdao 266104, China
2.
Municipal Engineering Research Center of Aquatic Biological Quality Evaluation and Application,Qingdao 266104, China

More Information

Received Date: July 04, 2023
Available Online: March 19, 2024

Graphical Abstract

Abstract

Abstract

Astaxanthin is a fat-soluble lutein carotenoid with good antioxidant, anti-inflammatory and immunomodulatory activities. However, its poor oral bioavailability lead to limited clinical application. Recently, in order to improve the bioavailability of astaxanthin, various types of nano-formulations have been widely studied. Nano-emulsion, liposome, solid lipid nanoparticles, chitosan and PLGA nanoparticles have been shown to effectively improve the oral bioavailability of astaxanthin. In this review, based on in vitro and in vivo studies, the research progress of nano-formulations for improving the oral bioavailability of astaxanthin are summarized, providing reference for the development of oral delivery of astaxanthin, and achieving its clinical application value in the future.
- astaxanthin,
- oral formulation,
- nanoparticles,
- bioavailability

FullText(HTML)

References (59)

References

[1]	XU L, YU H X, SUN H B, et al. Optimized nonionic emulsifier for the efficient delivery of astaxanthin nanodispersions to retina:in vivo and ex vivo evaluations[J]. Drug Deliv,2019,26(1):1222−1234. doi: 10.1080/10717544.2019.1682718
[2]	GUERIN M, HUNTLEY M E, OLAIZOLA M. Haematococcus astaxanthin:Applications for human health and nutrition[J]. Trends Biotechnol,2003,21(5):210−216. doi: 10.1016/S0167-7799(03)00078-7
[3]	FAKHRI S, ANEVA I Y, FARZAEI M H, et al. The neuroprotective effects of astaxanthin:Therapeutic targets and clinical perspective[J]. Molecules,2019,24(14):2640. doi: 10.3390/molecules24142640
[4]	PASHKOW F J, WATUMULL D G, CAMPBELL C L. Astaxanthin:A novel potential treatment for oxidative stress and inflammation in cardiovascular disease[J]. Am J Cardiol,2008,101(10A):58−68.
[5]	CHEN S Q, WANG J Y, FENG J T, et al. Research progress of astaxanthin nano-based drug delivery system:Applications, prospects and challenges?[J]. Front Pharmacol,2023,14:1102888. doi: 10.3389/fphar.2023.1102888
[6]	LAMSON N G, BERGER A, FEIN K C, et al. Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability[J]. Nat Biomed Eng,2020,4(1):84−96.
[7]	ABDOL WAHAB N R, MEOR MOHD AFFANDI M M R, FAKURAZI S, et al. Nanocarrier system:State-of-the-art in oral delivery of astaxanthin[J]. Antioxidants (Basel),2022,11(9):1676. doi: 10.3390/antiox11091676
[8]	ABDELAZIM K, GHIT A, ASSAL D, et al. Production and therapeutic use of astaxanthin in the nanotechnology era[J]. Pharmacol Rep,2023,75(4):771−790. doi: 10.1007/s43440-023-00488-y
[9]	BASIONY M, OUYANG L M, WANG D N, et al. Optimization of microbial cell factories for astaxanthin production:Biosynthesis and regulations, engineering strategies and fermentation optimization strategies[J]. Synth Syst Biotechnol,2022,7(2):689−704. doi: 10.1016/j.synbio.2022.01.002
[10]	YAQOOB Z, ARSHAD M S, IMRAN M, et al. Mechanistic role of astaxanthin derived from shrimp against certain metabolic disorders[J]. Food Sci Nutr,2021,10(1):12−20.
[11]	STACHOWIAK B, SZULC P. Astaxanthin for the food industry[J]. Molecules,2021,26(9):2666. doi: 10.3390/molecules26092666
[12]	ZHANG C Q, CHEN X X, TOO H P. Microbial astaxanthin biosynthesis:Recent achievements, challenges, and commercialization outlook[J]. Appl Microbiol Biotechnol,2020,104(13):5725−5737. doi: 10.1007/s00253-020-10648-2
[13]	LI J J, GUO C Y, WU J Y. Astaxanthin in liver health and disease:A potential therapeutic agent[J]. Drug Des Devel Ther,2020,14:2275−2285. doi: 10.2147/DDDT.S230749
[14]	PEREZ-LOPEZ P, GONZALEZ-GARCIA S, JERYES C, et al. Life cycle assessment of the production of the red antioxidant carotenoid astaxanthin by microalgae:from lab to pilot scale[J]. J Clean Prod,2014,64:332−344. doi: 10.1016/j.jclepro.2013.07.011
[15]	YU W J, LIU J G. Astaxanthin isomers:Selective distribution and isomerization in aquatic animals[J]. Aquaculture,2020,520:734915. doi: 10.1016/j.aquaculture.2019.734915
[16]	AMBATI R R, PHANG S M, RAVI S, et al. Astaxanthin:sources, extraction, stability, biological activities and its commercial applications-a review[J]. Mar Drugs,2014,12(1):128−152. doi: 10.3390/md12010128
[17]	OSTERLIE M, BJERKENG B, LIAAEN-JENSEN S. Accumulation of astaxanthin all-E, 9Z and 13Z geometrical isomers and 3 and 3' RS optical isomers in rainbow trout (Oncorhynchus mykiss) is selective[J]. J Nutr,1999,129(2):391−398. doi: 10.1093/jn/129.2.391
[18]	CHEN Y N, TIE S S, ZHANG X D, et al. Preparation and characterization of glycosylated protein nanoparticles for astaxanthin mitochondria targeting delivery[J]. Food Funct,2021,12(17):7718−7727. doi: 10.1039/D1FO01751A
[19]	SATOH T. Nutraceuticals[M]. Boston:Academic Press, 2016:531-539.
[20]	RADICE R P, LIMONGI A R, VIVIANO E, et al. Effects of astaxanthin in animal models of obesity-associated diseases:A systematic review and meta-analysis[J]. Free Radic Biol Med,2021,171:156−168. doi: 10.1016/j.freeradbiomed.2021.05.008
[21]	MICHAELIS K, HOFFMANN M M, DREIS S, et al. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain[J]. J Pharmacol Exp Ther,2006,317(3):1246−1253. doi: 10.1124/jpet.105.097139
[22]	MARTINEZ-ÁLVAREZ Ó, CALVO M M, GOMEZ-ESTACA J. Recent advances in astaxanthin micro/nanoencapsulation to improve its stability and functionality as a food ingredient[J]. Mar Drugs,2020,18(8):406. doi: 10.3390/md18080406
[23]	AHMADI A R, AYAZI-NASRABADI R. Astaxanthin protective barrier and its ability to improve the health in patients with COVID-19[J]. Iran J Microbiol,2021,13(4):434−441.
[24]	CHEN Y N, SU W T, TIE S S, et al. Advances of astaxanthin-based delivery systems for precision nutrition[J]. Trends Food Sci Technol,2022,127:63−73. doi: 10.1016/j.jpgs.2022.07.007
[25]	JIANG L, SUN Y, LU A, et al. Ionic liquids:Promising approach for oral drug delivery[J]. Pharm Res,2022,39(10):2353−2365. doi: 10.1007/s11095-022-03260-8
[26]	DATE A A, HANES J, ENSIGN L M. Nanoparticles for oral delivery:design, evaluation and state-of-the-art[J]. J Control Release,2016,240:504−526. doi: 10.1016/j.jconrel.2016.06.016
[27]	JAISWAL M, DUDHE R, SHARMA P K. Nanoemulsion:an advanced mode of drug delivery system[J]. 3 Biotech,2015,5(2):123−127. doi: 10.1007/s13205-014-0214-0
[28]	JEEVANANDAM J, CHAN Y S, DANQUAH M K. Nano-formulations of drugs:Recent developments, impact and challenges[J]. Biochimie,2016,128-129:99−112. doi: 10.1016/j.biochi.2016.07.008
[29]	SHEN X, FANG T Q, ZHENG J, et al. Physicochemical properties and cellular uptake of astaxanthin-loaded emulsions[J]. Molecules,2019,24(4):727. doi: 10.3390/molecules24040727
[30]	MEOR MOLD AFFANDI M M R, JULIANTO T, MAJEED A B A. Enhanced oral bioavailability of astaxanthin with droplet size reduction[J]. Food Sci Technol Res,2012,18:549−554.
[31]	CHEN Y N, SU W T, TIE S S, et al. Orally deliverable sequence-targeted astaxanthin nanoparticles for colitis alleviation[J]. Biomaterials,2023,293:121976. doi: 10.1016/j.biomaterials.2022.121976
[32]	GAO Q, QIAO X, YANG L, et al. Effects of microencapsulation in dairy matrix on the quality characteristics and bioavailability of docosahexaenoic acid astaxanthin[J]. J Sci Food Agric,2022,102(13):5711−5719.
[33]	LARGE D E, ABDELMESSIH R G, FINK E A, et al. Liposome composition in drug delivery design, synthesis, characterization, and clinical application[J]. Adv Drug Deliv Rev,2021,176:113851. doi: 10.1016/j.addr.2021.113851
[34]	KUMAR M, BISHNOI R S, SHUKLA A K, et al. Techniques for formulation of nanoemulsion drug delivery system:A review[J]. Prev Nutr Food Sci,2019,24(3):225−234. doi: 10.3746/pnf.2019.24.3.225
[35]	JAFARI Z, BIGHAM A, SADEGHI S, et al. Nanotechnology-abetted astaxanthin formulations in multimodel therapeutic and biomedical applications[J]. J Med Chem,2022,65(1):2−36. doi: 10.1021/acs.jmedchem.1c01144
[36]	PENG C H, CHANG C H, PENG R Y, et al. Improved membrane transport of astaxanthine by liposomal encapsulation[J]. Eur J Pharm Biopharm,2010,75(2):154−161. doi: 10.1016/j.ejpb.2010.03.004
[37]	SANGSURIYAWONG A, LIMPAWATTANA M, SIRIWAN D, et al. Properties and bioavailability assessment of shrimp astaxanthin loaded liposomes[J]. Food Sci Biotechnol,2018,28(2):529−537.
[38]	KAZI K M, MANDAL A S, BISWAS N, et al. Niosome:A future of targeted drug delivery systems[J]. J Adv Pharm Technol Res,2010,1(4):374−380. doi: 10.4103/0110-5558.76435
[39]	ROSTAMABADI H, FALSAFI S R, JAFARI S M. Nanoencapsulation of carotenoids within lipid-based nanocarriers[J]. J Control Release,2019,298:38−67. doi: 10.1016/j.jconrel.2019.02.005
[40]	SANTONOCITO D, RACITI G, CAMPISI A, et al. Astaxanthin-loaded stealth lipid nanoparticles (AST-SSLN) as potential carriers for the treatment of Alzheimer's disease:Formulation development and optimization[J]. Nanomaterials (Basel),2021,11(2):391. doi: 10.3390/nano11020391
[41]	MUCHOW M, MAINCENT P, MULLER R H. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery[J]. Drug Dev Ind Pharm,2008,34(12):1394−1405. doi: 10.1080/03639040802130061
[42]	ISLAN G A, CACCICEDO M L, BOSIO V E, et al. Advances in smart nanopreparations for oral drug delivery[J]. Smart Pharmaceutical Nanocarriers, 2015:479-521.
[43]	WANG T, HU Q, LEE J Y, et al. Solid lipid-polymer hybrid nanoparticles by in situ conjugation for oral delivery of astaxanthin[J]. J Agric Food Chem,2018,66(36):9473−9480. doi: 10.1021/acs.jafc.8b02827
[44]	LI M, ZAHI M R, YUAN Q, et al. Preparation and stability of astaxanthin solid lipid nanoparticles based on stearic acid[J]. Eur J Lipid Sci Technol,2016,118:592−602. doi: 10.1002/ejlt.201400650
[45]	JAIN P, RAHI P, PANDEY V, et al. Nanostructure lipid carriers:a modish contrivance to overcome the ultraviolet effects[J]. Egypt J Basic Appl Sci,2017,4:89−100.
[46]	HU Q B, HU S Q, FLEMING E, et al. Chitosan-caseinate-dextran ternary complex nanoparticles for potential oral delivery of astaxanthin with significantly improved bioactivity[J]. Int J Biol Macromol,2020,151:747−756. doi: 10.1016/j.ijbiomac.2020.02.170
[47]	KIM E S, BAEK Y, YOO H J, et al. Chitosan-tripolyphosphate nanoparticles prepared by ionic gelation improve the antioxidant activities of astaxanthin in the in vitro and in vivo model[J]. Antioxidants (Basel),2022,11(3):479. doi: 10.3390/antiox11030479
[48]	ZHU Y, GU Z Q, LIAO Y W, et al. Improved intestinal absorption and oral bioavailability of astaxanthin using poly (ethylene glycol)-graft-chitosan nanoparticles:Preparation, in vitro evaluation, and pharmacokinetics in rats[J]. J Sci Food Agric,2022,102(3):1002−1011. doi: 10.1002/jsfa.11435
[49]	GUAN L, LIU J L, YU H J Y, et al. Water-dispersible astaxanthin-rich nanopowder:Preparation, oral safety and antioxidant activity in vivo[J]. Food Funct,2019,10(3):1386−1397. doi: 10.1039/C8FO01593G
[50]	SADAT TABATABAEI MIRAKABAD F, NEJATI-KOSHKI K, AKBARZADEH A, et al. PLGA-based nanoparticles as cancer drug delivery systems[J]. Asian Pac J Cancer Prev,2014,15(2):517−535. doi: 10.7314/APJCP.2014.15.2.517
[51]	KU AIZUDDIN K A, NURLINA M A, KHURIAH A H, et al. Development of astaxanthin-loaded biodegradable nanoparticles by nanoprecipitation method[J]. Int J Pharm Technol,2014,5:5962−5972.
[52]	LIU C Z, ZHANG S Z, MCCLEMENTS D J, et al. Design of astaxanthin-loaded core-shell nanoparticles consisting of chitosan oligosaccharides and poly(lactic-co-glycolic acid):Enhancement of water solubility, stability, and bioavailability[J]. J Agric Food Chem,2019,67(18):5113−5121. doi: 10.1021/acs.jafc.8b06963
[53]	ZHANG D X, HE J, CUI J R, et al. Oral microalgae-nano integrated system against radiation-induced injury[J]. ACS Nano,2023,17(11):10560−10576. doi: 10.1021/acsnano.3c01502
[54]	MALAM Y, LOIZIDOU M, SEIFALIAN A M. Liposomes and nanoparticles:Nanosized vehicles for drug delivery in cancer[J]. Trends Pharmacol Sci,2009,30:592−599. doi: 10.1016/j.tips.2009.08.004
[55]	HANS M L, LOWMAN A M. Biodegradable nanoparticles for drug delivery and targeting[J]. Curr Opin Solid State Mater Sci,2002,6:319−327. doi: 10.1016/S1359-0286(02)00117-1
[56]	MULLER R H, MAASEN S, WEYHERS H, et al. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407[J]. J Drug Target,1996,4(3):161−170. doi: 10.3109/10611869609015973
[57]	GASPAR D P, FARIA V, QUINTAS J P, et al. Targeted delivery of lipid nanoparticles by means of surface chemical modification[J]. Curr Org Chem,2017,21:2360−2375.
[58]	贤凤, 程婉婷, 高静. 壳聚糖纳米粒子的制备方法及其作为药物递送载体的应用[J]. 化学试剂,2021,43(12):1615−1622. [XIAN F, CHENG W T, GAO J. A review on the preparation methods of chitosan nanoparticles and their applications as drug delivery carriers[J]. Chemical Reagents,2021,43(12):1615−1622.] XIAN F, CHENG W T, GAO J. A review on the preparation methods of chitosan nanoparticles and their applications as drug delivery carriers[J]. Chemical Reagents, 2021, 43（12）: 1615−1622.
[59]	GASPAR R. Regulatory issues surrounding nanomedicines:Setting the scene for the next generation of nanopharmaceuticals[J]. Nanomedicine,2007,2:143−147. doi: 10.2217/17435889.2.2.143